{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T17:46:33Z","timestamp":1775238393428,"version":"3.50.1"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010221","name":"Higher Education Commision, Pakistan","doi-asserted-by":"publisher","award":["20-5904\/NRPU\/R&D\/17"],"award-info":[{"award-number":["20-5904\/NRPU\/R&D\/17"]}],"id":[{"id":"10.13039\/501100010221","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Around 30% of the HCV infected patients can spontaneously clear the virus. Cumulative evidence suggests the role of neutralizing antibodies in such spontaneous resolution. Understanding the epitope specificity of such antibodies will inform the rational vaccine design as such information is limited to date. In addition to conformational epitope targeted antibodies, linear epitope specific antibodies have been identified that are broadly cross reactive against diverse HCV strains. In this study, we have characterized the potential role of three conserved linear epitopes in the spontaneous clearance of HCV.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We tested the reactivity of sera from chronic patients (CP) and spontaneous resolvers (SR) with linear peptides corresponding to three conserved regions of HCV envelope protein E2 spanning amino acids 412\u2013423, 523\u2013532 and 432\u2013443 using ELISA. Subsequently, we characterized the dependency of HCV neutralization by the reactive serum samples on the antibodies specific for these epitopes using pseudoparticle-based neutralization assay.<\/jats:p>\n<jats:p>In ELISA most of the CP sera showed reactivity to multiple peptides while most of the SR samples were reactive to a single peptide suggesting presence of more specific antibodies in the SR sera. In most of the HCVpp neutralizing sera of particular peptide reactivity the neutralization was significantly affected by the presence of respective peptide. HCV neutralization by CP sera was affected by multiple peptides while 75% of the HCVpp neutralizing SR sera were competed by the 432 epitope.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>These findings suggest that individuals who spontaneously resolve HCV infection at the acute phase, can produce antibodies specific for conserved linear epitopes, and those antibodies can potentially play a role in the spontaneous viral clearance. The epitope present in the 432\u2013443 region of E2 was identified as the primary neutralizing epitope with potential role in spontaneous viral clearance and this epitope potentiates for the design of immunogen for prophylactic vaccine.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0256816","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T17:24:50Z","timestamp":1630085090000},"page":"e0256816","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Characterization of linear epitope specificity of antibodies potentially contributing to spontaneous clearance of hepatitis C virus"],"prefix":"10.1371","volume":"16","author":[{"given":"Asma","family":"Ahsan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saira","family":"Dar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fareeha","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farkhanda","family":"Ghafoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Haroon","family":"Yousuf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7736-1072","authenticated-orcid":true,"given":"Syed","family":"Shahzad-ul-Hussan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,8,27]]},"reference":[{"issue":"34","key":"pone.0256816.ref001","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.3748\/wjg.v22.i34.7824","article-title":"Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes","volume":"22","author":"A Petruzziello","year":"2016","journal-title":"World J Gastroentero"},{"key":"pone.0256816.ref002","unstructured":"WHO. Global hepatitis report 2017. 2017."},{"issue":"Suppl(0)","key":"pone.0256816.ref003","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/MCG.0b013e3182872f29","article-title":"Epidemiology of hepatocellular carcinoma: consider the population","volume":"47","author":"S Mittal","year":"2013","journal-title":"J Clinic gastroenterol"},{"issue":"1","key":"pone.0256816.ref004","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00535-018-1503-x","article-title":"Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial","volume":"54","author":"T Takehara","year":"2019","journal-title":"J Gastroenterol"},{"key":"pone.0256816.ref005","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2147\/IDR.S153060","article-title":"Efficacy and safety of sofosbuvir-ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection","volume":"11","author":"OA Ahmed","year":"2018","journal-title":"Infect Drug Resist"},{"issue":"9","key":"pone.0256816.ref006","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S1473-3099(16)30005-6","article-title":"Access to treatment for hepatitis C virus infection: time to put patients first","volume":"16","author":"BR Edlin","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"pone.0256816.ref007","first-page":"110","article-title":"Barriers to Treatment Access for Chronic Hepatitis C Virus Infection: A Case Series","volume":"25","author":"AJ Millman","year":"2017","journal-title":"Top Antivir Med"},{"issue":"4","key":"pone.0256816.ref008","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2217\/fvl.13.11","article-title":"Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges","volume":"8","author":"M Lemoine","year":"2013","journal-title":"Future Virol"},{"key":"pone.0256816.ref009","first-page":"265","article-title":"DRUG PRICING & CHALLENGES TO HEPATITIS C TREATMENT ACCESS","volume":"14","author":"B Henry","year":"2018","journal-title":"Journal of health & biomedical law"},{"issue":"6","key":"pone.0256816.ref010","doi-asserted-by":"crossref","first-page":"831","DOI":"10.4254\/wjh.v7.i6.831","article-title":"Hepatitis C virus genetic variability and evolution","volume":"7","author":"N Echeverr\u00eda","year":"2015","journal-title":"World J Hepatol"},{"issue":"11","key":"pone.0256816.ref011","doi-asserted-by":"crossref","first-page":"5746","DOI":"10.3390\/v7112902","article-title":"Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications","volume":"7","author":"C Perales","year":"2015","journal-title":"Viruses"},{"issue":"3","key":"pone.0256816.ref012","first-page":"103","article-title":"Understanding Hepatitis C Virus Drug Resistance: Clinical Implications for Current and Future Regimens","volume":"25","author":"DL Wyles","year":"2017","journal-title":"Top Antivir Med"},{"issue":"7265","key":"pone.0256816.ref013","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus","volume":"461","author":"DL Thomas","year":"2009","journal-title":"Nature"},{"issue":"31","key":"pone.0256816.ref014","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.3748\/wjg.v13.i31.4224","article-title":"Spontaneous elimination of hepatitis C virus infection: a retrospective study on demographic, clinical, and serological correlates","volume":"13","author":"P Wietzke-Braun","year":"2007","journal-title":"World J Gastroenterol"},{"issue":"1","key":"pone.0256816.ref015","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/hep.26639","article-title":"The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection","volume":"59","author":"J Grebely","year":"2014","journal-title":"Hepatology"},{"issue":"6","key":"pone.0256816.ref016","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1002\/hep.27013","article-title":"Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses","volume":"59","author":"WO Osburn","year":"2014","journal-title":"Hepatology"},{"key":"pone.0256816.ref017","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.3389\/fimmu.2018.01917","article-title":"Hepatitis C Virus Envelope Glycoproteins: A Balancing Act of Order and Disorder","volume":"9","author":"SA Yost","year":"2018","journal-title":"Front Immunol"},{"issue":"7","key":"pone.0256816.ref018","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1093\/infdis\/jiz274","article-title":"Repertoire and Neutralizing Activity of Antibodies Against Hepatitis C Virus E2 Peptide in Patients With Spontaneous Resolution of Hepatitis C","volume":"220","author":"A Olbrich","year":"2019","journal-title":"J Infect Dis"},{"issue":"14","key":"pone.0256816.ref019","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1073\/pnas.0607026104","article-title":"Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C","volume":"104","author":"JM Pestka","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"pone.0256816.ref020","doi-asserted-by":"crossref","first-page":"7672","DOI":"10.1128\/JVI.76.15.7672-7682.2002","article-title":"Analysis of Antigenicity and Topology of E2 Glycoprotein Present on Recombinant Hepatitis C Virus-Like Particles","volume":"76","author":"RF Clayton","year":"2002","journal-title":"J Virol"},{"issue":"17","key":"pone.0256816.ref021","doi-asserted-by":"crossref","first-page":"8695","DOI":"10.1128\/JVI.00271-06","article-title":"Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding","volume":"80","author":"AM Owsianka","year":"2006","journal-title":"J Virol"},{"issue":"16","key":"pone.0256816.ref022","doi-asserted-by":"crossref","first-page":"7844","DOI":"10.1128\/JVI.00029-06","article-title":"A conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry","volume":"80","author":"HE Drummer","year":"2006","journal-title":"J Virol"},{"key":"pone.0256816.ref023","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.3389\/fimmu.2018.01315","article-title":"The Neutralizing Face of Hepatitis C Virus E2 Envelope Glycoprotein","volume":"9","author":"N Tzarum","year":"2018","journal-title":"Front Immunol"},{"key":"pone.0256816.ref024","doi-asserted-by":"crossref","first-page":"450963","DOI":"10.1155\/2013\/450963","article-title":"Structural and antigenic definition of hepatitis C virus E2 glycoprotein epitopes targeted by monoclonal antibodies","volume":"2013","author":"G Sautto","year":"2013","journal-title":"Clin Dev Immunol"},{"issue":"17","key":"pone.0256816.ref025","doi-asserted-by":"crossref","first-page":"11095","DOI":"10.1128\/JVI.79.17.11095-11104.2005","article-title":"Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein","volume":"79","author":"A Owsianka","year":"2005","journal-title":"J Virol"},{"issue":"23","key":"pone.0256816.ref026","doi-asserted-by":"crossref","first-page":"12473","DOI":"10.1128\/JVI.01138-09","article-title":"Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus","volume":"83","author":"TJ Broering","year":"2009","journal-title":"J Virol"},{"issue":"8","key":"pone.0256816.ref027","doi-asserted-by":"crossref","first-page":"e1002895","DOI":"10.1371\/journal.ppat.1002895","article-title":"Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees","volume":"8","author":"TJ Morin","year":"2012","journal-title":"PLoS Pathog"},{"issue":"5","key":"pone.0256816.ref028","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1099\/jgv.0.000735","article-title":"Identification of a novel epitope in the C terminus of hepatitis C virus-E2 protein that induces potent and cross-reactive neutralizing antibodies","volume":"98","author":"S Das","year":"2017","journal-title":"J Gen Virol"},{"issue":"Suppl 1","key":"pone.0256816.ref029","doi-asserted-by":"crossref","first-page":"S192","DOI":"10.1086\/514313","article-title":"ELISA for the detection of antibodies to Ebola viruses","volume":"179","author":"TG Ksiazek","year":"1999","journal-title":"J Infect Dis"},{"issue":"13","key":"pone.0256816.ref030","doi-asserted-by":"crossref","first-page":"6875","DOI":"10.1128\/JVI.78.13.6875-6882.2004","article-title":"Characterization of infectious retroviral pseudotype particles bearing hepatitis C virus glycoproteins","volume":"78","author":"M Flint","year":"2004","journal-title":"J Virol"},{"issue":"6","key":"pone.0256816.ref031","doi-asserted-by":"crossref","first-page":"e66872","DOI":"10.1371\/journal.pone.0066872","article-title":"Determination of the human antibody response to the neutralization epitopes encompassing amino acids 313\u2013327 and 432\u2013443 of hepatitis C virus E1E2 glycoproteins","volume":"8","author":"R Liu","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"pone.0256816.ref032","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1021\/acs.chemrev.9b00472","article-title":"Peptide-Based Vaccines: Current Progress and Future Challenges","volume":"120","author":"RJ Malonis","year":"2020","journal-title":"Chem Rev"},{"issue":"24","key":"pone.0256816.ref033","doi-asserted-by":"crossref","first-page":"6289","DOI":"10.3390\/ijms20246289","article-title":"Peptides, Antibodies, Peptide Antibodies and More","volume":"20","author":"N Trier","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"pone.0256816.ref034","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1128\/JVI.01661-14","article-title":"A View of the E2-CD81 Interface at the Binding Site of a Neutralizing Antibody against Hepatitis C Virus","volume":"89","author":"C Harman","year":"2015","journal-title":"J Virol"},{"issue":"6","key":"pone.0256816.ref035","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1002\/hep.28760","article-title":"Hepatitis C virus plays hide and seek with neutralizing antibodies","volume":"64","author":"D Bankwitz","year":"2016","journal-title":"Hepatology"},{"issue":"5","key":"pone.0256816.ref036","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1128\/JVI.06492-11","article-title":"Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization","volume":"86","author":"AW Tarr","year":"2012","journal-title":"J Virol"},{"issue":"3","key":"pone.0256816.ref037","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/hep.21088","article-title":"Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33","volume":"43","author":"AW Tarr","year":"2006","journal-title":"Hepatology"},{"issue":"8","key":"pone.0256816.ref038","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.vaccine.2014.12.061","article-title":"Increasing cellular immunogenicity to peptide-based vaccine candidates using a fluorocarbon antigen delivery system","volume":"33","author":"JN Francis","year":"2015","journal-title":"Vaccine"},{"issue":"14","key":"pone.0256816.ref039","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1073\/pnas.0607026104","article-title":"Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C","volume":"104","author":"JM Pestka","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"pone.0256816.ref040","doi-asserted-by":"crossref","first-page":"13300","DOI":"10.1038\/s41598-019-49454-w","article-title":"Clearance of hepatitis C virus is associated with early and potent but narrowly-directed, Envelope-specific antibodies","volume":"9","author":"MR Walker","year":"2019","journal-title":"Scie Rep"},{"issue":"20","key":"pone.0256816.ref041","doi-asserted-by":"crossref","first-page":"8449","DOI":"10.1073\/pnas.0703039104","article-title":"Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma","volume":"104","author":"P Zhang","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"pone.0256816.ref042","doi-asserted-by":"crossref","first-page":"7537","DOI":"10.1073\/pnas.0902749106","article-title":"Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity","volume":"106","author":"P Zhang","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"pone.0256816.ref043","doi-asserted-by":"crossref","first-page":"10584","DOI":"10.1128\/JVI.01402-14","article-title":"Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors","volume":"88","author":"M Lavie","year":"2014","journal-title":"J Virol"},{"issue":"5","key":"pone.0256816.ref044","doi-asserted-by":"crossref","first-page":"e0177383","DOI":"10.1371\/journal.pone.0177383","article-title":"A Sequence in the loop domain of hepatitis C virus E2 protein identified in silico as crucial for the selective binding to human CD81","volume":"12","author":"C-C Chang","year":"2017","journal-title":"PloS one"},{"issue":"6","key":"pone.0256816.ref045","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/hep.28108","article-title":"Antibodies to an interfering epitope in hepatitis C virus E2 can mask vaccine-induced neutralizing activity","volume":"62","author":"A Kachko","year":"2015","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"29","key":"pone.0256816.ref046","doi-asserted-by":"crossref","first-page":"10690","DOI":"10.1073\/pnas.1411317111","article-title":"Discrete conformations of epitope II on the hepatitis C virus E2 protein for antibody-mediated neutralization and nonneutralization","volume":"111","author":"L Deng","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"pone.0256816.ref047","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1053\/j.gastro.2009.02.080","article-title":"Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus","volume":"136","author":"KA Dowd","year":"2009","journal-title":"Gastroenterology"},{"issue":"1","key":"pone.0256816.ref048","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nm1698","article-title":"Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge","volume":"14","author":"M Law","year":"2008","journal-title":"Nat Med"},{"issue":"4","key":"pone.0256816.ref049","doi-asserted-by":"crossref","first-page":"e1002653","DOI":"10.1371\/journal.ppat.1002653","article-title":"Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate","volume":"8","author":"ZY Keck","year":"2012","journal-title":"PLoS Pathog"},{"issue":"5","key":"pone.0256816.ref050","doi-asserted-by":"crossref","first-page":"e1007772","DOI":"10.1371\/journal.ppat.1007772","article-title":"Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design","volume":"15","author":"ZY Keck","year":"2019","journal-title":"PloS Pathog"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0256816","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T17:25:34Z","timestamp":1630085134000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0256816"}},"subtitle":[],"editor":[{"given":"Sripathi M","family":"Sureban","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,8,27]]},"references-count":50,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0256816","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,27]]}}}